Literature DB >> 20670952

Adenovirus targeting to prostate-specific membrane antigen through virus-displayed, semirandom peptide library screening.

Ping Wu1, Tarana A Kudrolli, Wasim H Chowdhury, Minzhi M Liu, Ronald Rodriguez, Shawn E Lupold.   

Abstract

The convergence of phage-displayed peptide libraries and recombinant viral vectors launched a promising new direction in targeted viral gene therapeutics, but the translation of targeting peptides to functional cancer therapeutic agents has been challenging. Here, we report progress in developing a successful strategy to optimize targeted viral infection through adenovirus-displayed, semirandom peptide libraries. A phage-derived peptide targeting the prostate-specific membrane antigen (PSMA) was genetically incorporated into the adenoviral capsid Fiber protein and flanked by random peptide cassettes. The resulting adenovirus library was biopanned against PSMA-expressing cells and tumors to identify a PSMA-retargeted adenovirus. While the initial peptide alone could not target viral infection, the selected virus preferentially infects PSMA-expressing cells through the targeting peptide and infects LNCaP tumors after intravenous injection. Our results indicate that virus-displayed, semirandom peptide libraries can be used to optimize targeting infection. This approach represents a novel principle for developing targeted agents in a variety of disease models.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20670952      PMCID: PMC2995819          DOI: 10.1158/0008-5472.CAN-10-1760

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  Selection of muscle-binding peptides from context-specific peptide-presenting phage libraries for adenoviral vector targeting.

Authors:  Debadyuti Ghosh; Michael A Barry
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

2.  Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells.

Authors:  R Rodriguez; E R Schuur; H Y Lim; G A Henderson; J W Simons; D R Henderson
Journal:  Cancer Res       Date:  1997-07-01       Impact factor: 12.701

3.  Direct selection of targeted adenovirus vectors by random peptide display on the fiber knob.

Authors:  Y Miura; K Yoshida; T Nishimoto; K Hatanaka; S Ohnami; M Asaka; J T Douglas; D T Curiel; T Yoshida; K Aoki
Journal:  Gene Ther       Date:  2007-08-16       Impact factor: 5.250

4.  Armoring CRAds with p21/Waf-1 shRNAs: the next generation of oncolytic adenoviruses.

Authors:  N Höti; W H Chowdhury; S Mustafa; J Ribas; M Castanares; T Johnson; M Liu; S E Lupold; R Rodriguez
Journal:  Cancer Gene Ther       Date:  2010-05-07       Impact factor: 5.987

5.  Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting.

Authors:  Neus Bayo-Puxan; Manel Cascallo; Alena Gros; Meritxell Huch; Cristina Fillat; Ramon Alemany
Journal:  J Gen Virol       Date:  2006-09       Impact factor: 3.891

6.  A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity.

Authors:  Saurabh Aggarwal; Pratap Singh; Ozlem Topaloglu; John T Isaacs; Samuel R Denmeade
Journal:  Cancer Res       Date:  2006-09-15       Impact factor: 12.701

7.  Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae.

Authors:  P W Roelvink; G Mi Lee; D A Einfeld; I Kovesdi; T J Wickham
Journal:  Science       Date:  1999-11-19       Impact factor: 47.728

8.  A rapid and efficient method for purification of recombinant adenovirus with arginine-glycine-aspartic acid-modified fibers.

Authors:  Henry H Peng; Shuhong Wu; John J Davis; Li Wang; Jack A Roth; Frank C Marini; Bingliang Fang
Journal:  Anal Biochem       Date:  2006-05-03       Impact factor: 3.365

9.  Amphipathic peptide-based fusion peptides and immunoconjugates for the targeted ablation of prostate cancer cells.

Authors:  Kaushal Rege; Suraj J Patel; Zaki Megeed; Martin L Yarmush
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

Review 10.  Engineering targeted viral vectors for gene therapy.

Authors:  Reinhard Waehler; Stephen J Russell; David T Curiel
Journal:  Nat Rev Genet       Date:  2007-07-03       Impact factor: 53.242

View more
  10 in total

1.  2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.

Authors:  Ying Chen; Mrudula Pullambhatla; Catherine A Foss; Youngjoo Byun; Sridhar Nimmagadda; Srinivasan Senthamizhchelvan; George Sgouros; Ronnie C Mease; Martin G Pomper
Journal:  Clin Cancer Res       Date:  2011-10-31       Impact factor: 12.531

2.  A novel approach for detecting viable and tissue-specific circulating tumor cells through an adenovirus-based reporter vector.

Authors:  Ronald Rodriguez; Shawn E Lupold; Ping Wu; Lori J Sokoll; Tarana A Kudrolli; Wasim H Chowdhury; Rong Ma; Minzhi M Liu
Journal:  Prostate       Date:  2014-07-25       Impact factor: 4.104

3.  Prostate-specific membrane antigen targeted protein contrast agents for molecular imaging of prostate cancer by MRI.

Authors:  Fan Pu; Mani Salarian; Shenghui Xue; Jingjuan Qiao; Jie Feng; Shanshan Tan; Anvi Patel; Xin Li; Kenza Mamouni; Khan Hekmatyar; Juan Zou; Daqing Wu; Jenny J Yang
Journal:  Nanoscale       Date:  2016-03-10       Impact factor: 7.790

Review 4.  Retargeting adenoviruses for therapeutic applications and vaccines.

Authors:  Michael A Barry; Jeffrey D Rubin; Shao-Chia Lu
Journal:  FEBS Lett       Date:  2020-02-03       Impact factor: 4.124

5.  Retargeted and detargeted adenovirus for gene delivery to the muscle.

Authors:  Tien V Nguyen; Stephanie S Anguiano-Zarate; William E Matchett; Mary E Barry; Michael A Barry
Journal:  Virology       Date:  2017-11-22       Impact factor: 3.616

6.  Development of peritoneal tumor-targeting vector by in vivo screening with a random peptide-displaying adenovirus library.

Authors:  Takeshi Nishimoto; Yuki Yamamoto; Kimiko Yoshida; Naoko Goto; Shumpei Ohnami; Kazunori Aoki
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

Review 7.  Advances and future challenges in adenoviral vector pharmacology and targeting.

Authors:  Reeti Khare; Christopher Y Chen; Eric A Weaver; Michael A Barry
Journal:  Curr Gene Ther       Date:  2011-08       Impact factor: 4.391

8.  Adenoviruses using the cancer marker EphA2 as a receptor in vitro and in vivo by genetic ligand insertion into different capsid scaffolds.

Authors:  Michael Behr; Johanna K Kaufmann; Patrick Ketzer; Sarah Engelhardt; Martin Mück-Häusl; Pamela M Okun; Gabriele Petersen; Frank Neipel; Jessica C Hassel; Anja Ehrhardt; Alexander H Enk; Dirk M Nettelbeck
Journal:  PLoS One       Date:  2014-04-23       Impact factor: 3.240

Review 9.  Recent advances in genetic modification of adenovirus vectors for cancer treatment.

Authors:  Yuki Yamamoto; Masaki Nagasato; Teruhiko Yoshida; Kazunori Aoki
Journal:  Cancer Sci       Date:  2017-05-07       Impact factor: 6.716

Review 10.  Gene Therapy Leaves a Vicious Cycle.

Authors:  Reena Goswami; Gayatri Subramanian; Liliya Silayeva; Isabelle Newkirk; Deborah Doctor; Karan Chawla; Saurabh Chattopadhyay; Dhyan Chandra; Nageswararao Chilukuri; Venkaiah Betapudi
Journal:  Front Oncol       Date:  2019-04-24       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.